Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

NCT02556372 is registered in ClinicalTrials.gov with TaiwanJ Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT02556372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02556372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2016
Completion date
January 21, 2019
Enrollment
20 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hepatitis